StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $1.33 | $1.31 | -1.50% | 0.1M |
| 05-18 | $1.31 | $1.27 | -3.05% | 0.2M |
| 05-19 | $1.25 | $1.25 | +0.00% | 0.1M |
| 05-20 | $1.26 | $1.29 | +2.38% | 0.2M |
| 05-21 | $1.30 | $1.30 | +0.00% | 0.1M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $1.25M | $25.21M | $21.30M | $12.64M |
Operating Income | $-24.59M | $-96.01M | $-71.65M | $-48.81M |
Net Income | $-23.06M | $-87.87M | $-65.34M | $-19.91M |
EPS (Diluted) | $-0.61 | $-2.36 | $-1.76 | $-1.21 |
Total Assets | $196.95M | $221.10M | $247.94M | $272.28M |
Total Liabilities | $59.17M | $62.51M | $69.49M | $76.45M |
Cash & Equivalents | $25.31M | $41.72M | $32.77M | $26.85M |
Free Cash Flow OCF − CapEx | $-21.20M | $-89.47M | $-65.83M | $-44.51M |
Shares Outstanding | 37.65M | 37.62M | 37.55M | 37.53M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.